-
Mashup Score: 2BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints - 12 hour(s) ago
Evan David Seigerman, BMO managing director, joins ‘Fast Money’ to discuss Novo sinking on its obesity drug data.
Source: stocks.apple.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2A roadmap to better health in the USA - 14 hour(s) ago
On Jan 20, 2025, the Trump administration will take charge at a crucial time for health in the USA. To address the seriousness of the task ahead, The Lancet today publishes what can serve as a presidential briefing book, bringing together the best evidence on the state of health in the USA and some solutions for improving it.
Source: www.thelancet.comCategories: General Medicine News, General HCPsTweet-
A roadmap to better #health in the #USA @TheLancet https://t.co/VQNNgyASse
-
-
Mashup Score: 0A Population Based Study of Bariatric Surgery in Illinois - 15 hour(s) ago
Utilization of metabolic and bariatric surgery has increased significantly over the last two decades, yet barriers to access remain.
Source: www.soard.orgCategories: General Medicine News, General HCPsTweet-
A Population Based Study of Bariatric Surgery in Illinois - Surgery for Obesity and Related Diseases #SOARD #BariatricSurgery #obesity https://t.co/ckhtPvque8
-
-
Mashup Score: 5Assessment and medical management of weight regain after adolescent metabolic and bariatric surgery: a narrative review - 15 hour(s) ago
Metabolic and bariatric surgery (MBS) in adolescents results in durable treatment of severe obesity and related complications for most. However, substantial weight regain can undermine long-term health benefits. There is no evidence-based standard of care for the medical management of weight regain after MBS in pediatrics or adults. This narrative review summarizes current pediatric evidence pertaining to the assessment and medical management of post-MBS weight regain, identifies gaps, and offers recommendations.
Source: www.soard.orgCategories: General Medicine News, General HCPsTweet-
Assessment and medical management of weight regain after adolescent metabolic and bariatric surgery: a narrative review - Surgery for Obesity and Related Diseases https://t.co/4fe0dpXLqZ
-
-
Mashup Score: 5Cold induces increased ad libitum energy intake independent of changes in energy expenditure: a controlled crossover trial in adults - 15 hour(s) ago
Measures of energy metabolism [energy expenditure (EE), respiratory exchange ratio (RER)] have been associated with ad libitum energy intake (EI) and weight gain in previous observational studies, suggesting that energy-sensing mechanisms drive EI to meet metabolic energy demands.
Source: ajcn.nutrition.orgCategories: General Medicine News, General HCPsTweet-
Cold induces increased ad libitum energy intake independent of changes in energy expenditure: a controlled crossover trial in adults - The American Journal of Clinical Nutrition https://t.co/NIu28rivhh
-
-
Mashup Score: 4On Ozempic? Big Food Makers Have a New Label for You - 2 day(s) ago
Conagra Brands adding ‘GLP-1 friendly’ to packaging on Healthy Choice frozen meals to woo users of weight-loss drugs
Source: apple.newsCategories: General Medicine News, General HCPsTweet-
For the first time: anti-obesity medications are influencing food producers to adjust food marketing How far we have come…. Big food brands are adding a new label to their products — for customers on Ozempic - The Wall Street Journal https://t.co/gbTvchhGRp
-
-
Mashup Score: 5
Harmful chemicals and microplastics might not be the extra ingredients you want in your meals
Source: apple.newsCategories: General Medicine News, General HCPsTweet-
Yup! Your kitchen equipment could be poisoning you. Here's what to replace - BBC Science Focus Magazine https://t.co/H2rD1Gd2oh
-
-
Mashup Score: 8
The experimental obesity drug CagriSema disappointed investors.
Source: stocks.apple.comCategories: General Medicine News, General HCPsTweet-
Investors have there eyes on obesity drugs and they don’t like the results: Novo Nordisk Stock Crashes on Obesity Drug Data. It’s a Win for Eli Lilly. - @Barron’s https://t.co/enpX5wl5tO
-
-
Mashup Score: 4
With the Biden administration pushing for Medicare, Medicaid coverage of GLP-1s, analysts disagree on whether it will decrease obesity costs.
Source: www.medscape.comCategories: General Medicine News, General HCPsTweet-
RT @BevTchangMD: Could Paying for #Obesity Medications Offset Obesity Care Costs?https://t.co/95HSB6Vfrz @medscape
-
-
Mashup Score: 38
Metabolic disease risk in individuals with obesity is variable and influenced by so-far-unknown factors. Reinisch and Ghosh et al. uncovered distinct cell populations and transcriptional programs in adipose tissue that are strongly linked to metabolic disease. The findings suggest that visceral adipose tissue plasticity is key to maintaining metabolic health despite excess adiposity.
Source: www.cell.comCategories: General Medicine News, General HCPsTweet-
RT @Cell_Metabolism: New! Online now: Unveiling adipose populations linked to metabolic health in obesity https://t.co/1KWJU66YtW https://…
-
I am NOT an economist but the Novo results outstanding and the negative reviews and price cuts only serve to create a HUGE buying opportunity for NOVO BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints @CNBC https://t.co/1rMGmTrsuh